Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891997 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL3102982 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL5891994 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL8390578 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL578556 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL8391473 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL5892033 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL5011436 | 1.00 | CHRM2 (0.55) | CHRM2DNM1TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28266997 | 0.97 | CHRM2 (0.52) | CHRM2DNM1TSHRMEN1KMT2A | |
| SCHEMBL177755 | 0.97 | CHRM2 (0.50) | CHRM2DNM1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4521507-A1 | ELECTROLYTE, SODIUM ION SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC APPARATUS | Contemporary Amperex Technology (Hong Kong) Limited (HK) | 2025-03-12 | — | — | EP | claimed |
| US-20250070252-A1 | ELECTROLYTE, SODIUM-ION SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC APPARATUS | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2025-02-27 | — | — | US | claimed |
| CN-118421255-B | Temperature-resistant high-viscosity adhesive and preparation method thereof | 山东凯恩新材料科技有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-118421255-A | Temperature-resistant high-viscosity adhesive and preparation method thereof | 山东凯恩新材料科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118160125-A | Electrolyte, sodium ion secondary battery, battery module, battery pack, and electricity using device | 宁德时代新能源科技股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-109554004-B | Pigment dispersants and their use | 江苏丽王科技股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-111020649-B | Leveling agent and preparation method thereof, electroplating solution and application thereof, electroplating method of circuit board and circuit board | 东莞市康迈克电子材料有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-112225697-A | Preparation method of enantiomer pure chloroquine and chloroquine phosphate | 宁波大学 | 2021-01-15 | — | — | CN | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10099172-B2 | Carbon dioxide absorbent comprising triamine | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2018-10-16 | — | — | US | claimed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | claimed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | claimed |
| US-6617324-B1 | Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted | G. D. SEARLE & COMPANY | 2003-09-09 | — | — | US | claimed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | claimed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | claimed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | claimed |
| EP-0298096-A1 | METHOD FOR STABILIZING CLAYISH FORMATIONS | CECA S.A. (FR) | 1989-01-11 | — | — | EP | claimed |
| WO-1988004680-A1 | METHOD FOR STABILIZING CLAYISH FORMATIONS | CECA S.A. (FR) | 1988-06-30 | — | — | WO | claimed |
| US-4088507-A | COPPER PHTHALOCYANINE AND DERIVATIVES | TOYO INK MANUFACTURING CO., LTD. (JA) | 1978-05-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CHRM2 126/4885DNM1 4081/4885TSHR 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.